Bio Elpida, your CDMO for Autologous or Allogenic Anti-Cancer Vaccine

From Development to Logistics and Pharmaceutical Release

Specialized in cell therapy, Bio Elpida is involved in sub-contracting development of autologous and allogenic anti-cancer vaccines.

Developments and clinical production of autologous and allogenic anti-cancer vaccines are undergoing for various partners. In February 2015, one became public: the first therapeutic vaccine against glioblastoma to be used in a Phase II clinical trial in the US.

An autologous cell therapy is a therapy using cells from the patient him/herself (rather than those of a donor). Cells are sampled during a biopsy and treated in vitro (culture, irradiation, labelling…) before being re-injected to the very same person.

In the case of the autologous anti-cancer vaccine, tumour cells are sampled, treated and re-injected. Treated cells induce an immune response that will ultimately lead to the destruction of all cancer cells present within the patient.